The firm's analyst highlighted recent clinical trial results presented at ESMO 2023 for BioNTech's investigational therapy, BNT211, which targets Claudin-6 in advanced solid tumors. At the ...

The firm's analyst highlighted recent clinical trial results presented at ESMO 2023 for BioNTech's investigational therapy, BNT211, which targets Claudin-6 in advanced solid tumors. At the European ...

H.C. Wainwright analyst Robert Burns has reiterated their bullish stance on BNTX stock, giving a Buy rating on September 9. Robert Burns has ...

(Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected assets from its multi-platform oncology pipeline at the European Society for Molecular Oncology (“ESMO”) ...

H.C. Wainwright reaffirmed its Buy rating for BioNTech, highlighting the clinical trial results for the investigational therapy, BNT211. JPMorgan upgraded BioNTech's stock from Underweight to ...

BNT211 combines autologous CAR-T cells directed ... is consistent with the previously published data of CAR-T therapies. BioNTech has established a diversified clinical oncology pipeline including ...

H.C. Wainwright reaffirmed its Buy rating for BioNTech, highlighting the clinical trial results for the investigational therapy, BNT211. JPMorgan (NYSE:JPM) upgraded BioNTech's stock from Underweight ...

the investigational CAR-T cell therapy BNT211, and the investigational ADC therapy BNT323/DB-1303; the nature and characterization of and timing for release of clinical data across BioNTech’s ...

BNT211 already has orphan drug and fast-track ... at approximately 35%. BioNTech and Regeneron are competing with rivals Moderna and MSD in the mRNA melanoma jab category, with the latter a ...